Bellicum Pharma (BLCM) Licenses Its CaspaCIDe Safety Switch to MD Anderson

Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that The University of Texas MD Anderson Cancer Center exercised its option to license Bellicum’s CaspaCIDe® safety switch technology.

Under terms of the original license agreement, MD Anderson’s decision to exercise the option entitled Bellicum to receive an upfront payment of $5 million, to be recognized in the fourth quarter 2019 financial results, and undisclosed future milestone payments and royalties on sales. The license agreement with Bellicum specifically covers use of the CaspaCIDe safety switch in MD Anderson’s CD19-directed chimeric antigen receptor natural killer (CAR NK) cell construct.

“We are excited that MD Anderson recognizes the utility of our CaspaCIDe safety switch technology,” said Rick Fair, President and Chief Executive Officer of Bellicum Pharmaceuticals. “We believe that the addition of CaspaCIDe to therapies like their CD19 CAR NK program can enable physicians to provide additional protection for patients.”

You May Also Be Interested In

• Ball Corporation (BALL) Raises Dividend, Enters 40M Share Buyback, Announces Management Changes
• Methanex (MEOH) Tops Q1 EPS by 35c
• VIST Financial Corp. (VIST) Misses Q1 EPS by 19c